bladder tumor tissues; paracarcinoma tissues; human bladder tissue specimens; blood samples; tumor tissues
SV-HUC-1; 293T; J82; T24
cell line-derived xenograft
MAPK (promotes); proliferation (promotes); migration (promotes); apoptosis (inhibits); cell cycle (promotes); ceRNA regulation (promotes); other pathway/process (promotes)
RNase R Treatment; RT-qPCR; Microarray; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; BrdU; Wound Healing Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis
circCEP128 was overexpressed in higher tumor differentiation stage, III-IV T stage, and N2-N3 lymph node metastasis stage of bladder cancer, suggesting association with advanced clinicopathologic features.
circCEP128 is upregulated in bladder cancer tissues, blood, and bladder cancer cells. It promotes bladder cancer progression by sponging miR-145-5p, increasing MYD88 and activating downstream MAPK signaling proteins; its knockdown suppresses proliferation, migration, cell cycle progression and xenograft tumor growth while increasing apoptosis.
0.8325
Circular RNA CEP128 promotes bladder cancer progression by regulating Mir-145-5p/Myd88 via MAPK signaling pathway.
combined biological and clinical study